首页> 外国专利> Treating auto-immune disease with platelet activating factor - opt. formulated with immunosuppressant, esp. for idiopathic thrombocytopaenic purpura

Treating auto-immune disease with platelet activating factor - opt. formulated with immunosuppressant, esp. for idiopathic thrombocytopaenic purpura

机译:用血小板活化因子治疗自身免疫性疾病-opt。配制有免疫抑制剂,特别是用于特发性血小板减少性紫癜

摘要

The use of PAF (platelet activating factor) antagonists (I) for treatment of autoimmune diseases, specifically idiopathic thrombocytopaenic purpura (ITP) is new. (I) is pref. a thieno(3,2-f) (1,2,4)-triazolo (4,3-a) (1,4) diazepine or (1,2,4) triazolo (4,3-a) (1,4) benzodiazepine deriv. and (II) is cyclosporin. (I) is 6-(2-chlorophenyl)-8,9-dihydro-1 -methyl-8-R-4H,7H cyclopenta (4,5) thieno (3,2-f) (1,2,4) triasolo (4,3-a) (1,4) diazepine (R = 4-morpholinylcarbonyl or dipropylaminocarbonyl) or 4-(2-chlorophenyl)-9- methyl -2-(3-(4-morpholinyl)-3-propanon-1-yl)-6H- thieno (3,2-f) (1,2,4) triazolo (4,3-a) (1,4) diazepine (Ia). USE/ADVANTAGE - (I) are effective against ITP, causing a rapid increase in the thrombocyte count, without the side effects associated with steroid therapy. Usual doses are 5-50 mg orally or 2.5-30 mg intravenously. When formulated with (II), (I) allows the dose (and thus the side effects) of (II) to be reduced.
机译:PAF(血小板活化因子)拮抗剂(I)用于治疗自身免疫性疾病,特别是特发性血小板减少性紫癜(ITP)的用途是新的。 (I)是首选。 Thieno(3,2-f)(1,2,4)-triazolo(4,3-a)(1,4)diazepine或(1,2,4)triazolo(4,3-a)(1, 4)苯二氮卓衍生物。 (II)是环孢菌素。 (I)是6-(2-氯苯基)-8,9-二氢-1-甲基-8-R-4H,7H环戊(4,5)噻诺(3,2-f)(1,2,4)三唑(4,3-a)(1,4)二氮杂(R = 4-吗啉基羰基或二丙基氨基羰基)或4-(2-氯苯基)-9-甲基-2-(3-(4-吗啉基)-3-丙烷-1-基)-6H-噻吩并(3,2-f)(1,2,4)三唑(4,3-a)(1,4)二氮杂(Ia)。使用/优点-(I)对ITP有效,可引起血小板计数快速增加,而没有类固醇疗法的副作用。通常的剂量是口服5-50mg或静脉内2.5-30mg。当与(II)一起配制时,(I)允许减少(II)的剂量(因此副作用)。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号